Non-peptidic guanidinium-functionalized silica nanoparticles as selective mitochondria-targeting drug nanocarriers
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, Junho | - |
dc.contributor.author | Lee, Boeun | - |
dc.contributor.author | Choi, Yeonweon | - |
dc.contributor.author | Jin, Hanyong | - |
dc.contributor.author | Lim, Na Young | - |
dc.contributor.author | Park, Jaehyeon | - |
dc.contributor.author | Kim, Ju Hyun | - |
dc.contributor.author | Bae, Jeehyeon | - |
dc.contributor.author | Jung, Jong Hwa | - |
dc.date.available | 2019-01-22T12:38:06Z | - |
dc.date.issued | 2018-09 | - |
dc.identifier.issn | 2050-750X | - |
dc.identifier.issn | 2050-7518 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/783 | - |
dc.description.abstract | We report on the design and fabrication of a Fe3O4 core-mesoporous silica nanopartide shell (Fe3O4@MSNs)-based mitochondria-targeting drug nanocarrier. A guanidinium derivative (GA) was conjugated onto the Fe3O4@MSNs as the mitochondria-targeting ligand. The fabrication of the Fe3O4@MSNs and their functionalization with GA were carried out by the sol-gel polymerization of alkoxysilane groups. Doxorubicin (DOX), an anti-cancer drug, was loaded into the pores of a GA-attached Fe3O4@MSNs due to both its anti-cancer properties and to allow for the fluorescent visualization of the nanocarriers. The selective and efficient mitochondria-targeting ability of a DOX-loaded GA-Fe3O4@MSNs (DOX/GA-Fe3O4@MSNs) was demonstrated by a co-localization study, transmission electron microscopy, and a fluorometric analysis on isolated mitochondria. It was found that the DOX/GA-Fe3O4@MSNs selectively accumulated into mitochondria within only five minutes; to the best of our knowledge, this is the shortest accumulation time reported for mitochondria targeting systems. Moreover, 2.6 times higher amount of DOX was accumulated in mitochondria by DOX/GA-Fe3O4@MSNs than by DOX/TPP-Fe3O4@MSNs. A cell viability assay indicated that the DOX/GA-Fe3O4@MSNs have high cytotoxicity to cancer cells, whereas the GA-Fe3O4@MSNs without DOX are non-cytotoxic; this indicates that the DOX/GA-Fe3O4@MSNs have great potential for use as biocompatible and effective mitochondria-targeting nanocarriers for cancer therapy. | - |
dc.format.extent | 10 | - |
dc.publisher | ROYAL SOC CHEMISTRY | - |
dc.title | Non-peptidic guanidinium-functionalized silica nanoparticles as selective mitochondria-targeting drug nanocarriers | - |
dc.type | Article | - |
dc.identifier.doi | 10.1039/c8tb01358f | - |
dc.identifier.bibliographicCitation | JOURNAL OF MATERIALS CHEMISTRY B, v.6, no.36, pp 5698 - 5707 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000448413200004 | - |
dc.identifier.scopusid | 2-s2.0-85053695331 | - |
dc.citation.endPage | 5707 | - |
dc.citation.number | 36 | - |
dc.citation.startPage | 5698 | - |
dc.citation.title | JOURNAL OF MATERIALS CHEMISTRY B | - |
dc.citation.volume | 6 | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | MOLECULAR TRANSPORTERS | - |
dc.subject.keywordPlus | CANCER-THERAPY | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | MAGNETIC-RESONANCE | - |
dc.subject.keywordPlus | DELIVERY SYSTEM | - |
dc.subject.keywordPlus | LUNG-CANCER | - |
dc.subject.keywordPlus | RELEASE | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | RICH | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.relation.journalResearchArea | Materials Science | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Biomaterials | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.